CN114174271A - 吡嗪-2(1h)-酮类化合物的c晶型和e晶型及其制备方法 - Google Patents

吡嗪-2(1h)-酮类化合物的c晶型和e晶型及其制备方法 Download PDF

Info

Publication number
CN114174271A
CN114174271A CN202080054562.8A CN202080054562A CN114174271A CN 114174271 A CN114174271 A CN 114174271A CN 202080054562 A CN202080054562 A CN 202080054562A CN 114174271 A CN114174271 A CN 114174271A
Authority
CN
China
Prior art keywords
degrees
compound
formula
crystalline form
crystal form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080054562.8A
Other languages
English (en)
Other versions
CN114174271B (zh
Inventor
洪绯
黄进明
高龙辉
王世聪
殷婷婷
付志飞
罗妙荣
张杨
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Original Assignee
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhangzhou Pientzehuang Pharmaceutical Co Ltd filed Critical Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Publication of CN114174271A publication Critical patent/CN114174271A/zh
Application granted granted Critical
Publication of CN114174271B publication Critical patent/CN114174271B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

一种吡嗪‑2(1H)‑酮类化合物的晶型及其制备方法，具体涉及式(II)化合物及其晶型的制备方法。

Description

PCT国内申请，说明书已公开。

Claims (23)

  1. PCT国内申请，权利要求书已公开。
CN202080054562.8A 2019-08-08 2020-08-04 吡嗪-2(1h)-酮类化合物的c晶型和e晶型及其制备方法 Active CN114174271B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910731661 2019-08-08
CN2019107316614 2019-08-08
CN2019110599695 2019-11-01
CN201911059969 2019-11-01
PCT/CN2020/106896 WO2021023194A1 (zh) 2019-08-08 2020-08-04 吡嗪-2(1h)-酮类化合物的c晶型和e晶型及其制备方法

Publications (2)

Publication Number Publication Date
CN114174271A true CN114174271A (zh) 2022-03-11
CN114174271B CN114174271B (zh) 2023-09-12

Family

ID=74503321

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080054562.8A Active CN114174271B (zh) 2019-08-08 2020-08-04 吡嗪-2(1h)-酮类化合物的c晶型和e晶型及其制备方法

Country Status (6)

Country Link
US (1) US11680061B2 (zh)
EP (1) EP4011867B1 (zh)
JP (1) JP7198387B2 (zh)
CN (1) CN114174271B (zh)
ES (1) ES2960702T3 (zh)
WO (1) WO2021023194A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021023192A1 (zh) * 2019-08-08 2021-02-11 漳州片仔癀药业股份有限公司 吡嗪-2(1h)-酮类化合物的a晶型和b晶型及其制备方法
EP4011867B1 (en) * 2019-08-08 2023-08-23 Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. Crystal forms c and e of pyrazin-2(1h)-one compound and preparation method therefor
US11597722B2 (en) * 2019-08-08 2023-03-07 Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. Crystal form D of pyrazine-2(1H)-ketone compound and preparation method therefor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009058076A1 (en) * 2007-11-02 2009-05-07 Astrazeneca Ab 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
CN103370314A (zh) * 2010-11-29 2013-10-23 阿斯特克斯治疗有限公司 作为用于治疗癌症疾病的fgfr激酶抑制剂的取代苯并吡嗪衍生物
CN107438607A (zh) * 2015-02-20 2017-12-05 因赛特公司 作为fgfr抑制剂的双环杂环
WO2019154364A1 (zh) * 2018-02-08 2019-08-15 南京明德新药研发有限公司 作为fgfr抑制剂的吡嗪-2(1h)-酮类化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3365335B1 (en) 2015-10-23 2024-02-14 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
KR20210071094A (ko) * 2018-11-19 2021-06-15 매슨 테크놀로지 인크 워크피스 처리를 위한 시스템 및 방법
WO2021023192A1 (zh) 2019-08-08 2021-02-11 漳州片仔癀药业股份有限公司 吡嗪-2(1h)-酮类化合物的a晶型和b晶型及其制备方法
EP4011867B1 (en) 2019-08-08 2023-08-23 Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. Crystal forms c and e of pyrazin-2(1h)-one compound and preparation method therefor
JP7121218B1 (ja) 2019-08-08 2022-08-17 ▲ザン▼州片仔▲ファン▼薬業股▲フン▼有限公司 ピラジン－２（１ｈ）－オン系化合物の製造方法
US11597722B2 (en) 2019-08-08 2023-03-07 Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. Crystal form D of pyrazine-2(1H)-ketone compound and preparation method therefor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009058076A1 (en) * 2007-11-02 2009-05-07 Astrazeneca Ab 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
CN103370314A (zh) * 2010-11-29 2013-10-23 阿斯特克斯治疗有限公司 作为用于治疗癌症疾病的fgfr激酶抑制剂的取代苯并吡嗪衍生物
CN107438607A (zh) * 2015-02-20 2017-12-05 因赛特公司 作为fgfr抑制剂的双环杂环
WO2019154364A1 (zh) * 2018-02-08 2019-08-15 南京明德新药研发有限公司 作为fgfr抑制剂的吡嗪-2(1h)-酮类化合物

Also Published As

Publication number Publication date
JP2022536560A (ja) 2022-08-17
EP4011867A4 (en) 2022-11-09
EP4011867A1 (en) 2022-06-15
US20220289722A1 (en) 2022-09-15
US11680061B2 (en) 2023-06-20
CN114174271B (zh) 2023-09-12
JP7198387B2 (ja) 2022-12-28
ES2960702T3 (es) 2024-03-06
WO2021023194A1 (zh) 2021-02-11
EP4011867B1 (en) 2023-08-23

Similar Documents

Publication Publication Date Title
CN114174271A (zh) 吡嗪-2(1h)-酮类化合物的c晶型和e晶型及其制备方法
CN114174272B (zh) 吡嗪-2(1h)-酮类化合物的制备方法
CN114174270B (zh) 吡嗪-2(1h)-酮类化合物的a晶型和b晶型及其制备方法
CN114269723B (zh) 吡嗪-2(1h)-酮类化合物的d晶型及其制备方法
CN110023288B (zh) 酪氨酸激酶抑制剂的晶型、盐型以及制备方法
CN111479809A (zh) 一种TGF-βRI抑制剂的晶型、盐型及其制备方法
CN108368111A (zh) 吡啶并[1,2-a]嘧啶酮类似物的晶型及其制备方法和中间体
EP3896063B1 (en) Crystalline forms of the syk inhibitor 5-fluoro-1-methyl-3-[[5-[4-(3-oxetanyl)-1-piperazinyl]-2-pyridinyl]amino]-6-(1h-pyrazol-3-yl)-2(1h)-quinolinone hydrochloride salt (1:1)
CN113646312B (zh) 固体形式的brd4抑制剂化合物及其制备方法与应用
WO2020164603A1 (zh) 固体形式的fgfr抑制剂化合物及其制备方法
CN111527073B (zh) 一种4-(萘-1-基)-4h-1,2,4-三唑类类化合物的晶型、盐型及其制备方法
KR20240004588A (ko) 피롤로피리미딘류 화합물의 결정형 및 이의 제조 방법
CN113825760A (zh) 一种mTORC1/2双激酶活性抑制剂的盐型、晶型及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant